Cell line · CVCL_0511
Papers182
1 to 20 of 182
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Anti-PD-L1 scFv-secreting fifth-generation GD2-CAR T cells enhance antitumor function against GD2-low retinoblastoma. | Mol Ther Nucleic Acids | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A metabolic-oxidative axis contributes to NK cell cryo-vulnerability. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| PARP Inhibitors plus Anlotinib as Bridging Therapy for Armored CAR-T Cells in Ovarian Cancer Enhances Infiltration and Antitumor Efficacy. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Meditope-Enabled Chimeric Antigen Receptors Facilitate Plug-and-Play Control of T Cells. | Cancer Immunol Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting CD24 Activates Macrophages to Reduce Tumor Burden in Preclinical Models of Solid Tumors. | Clin Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A first-in-class bifunctional antibody targeting CD20 and CD37 remodels the immune microenvironment in relapsed or refractory B-cell malignancies. | J Hematol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A high-throughput modular microfluidic platform for versatile functional assays at single-cell level. | Microsyst Nanoeng | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Optimizing Zirconium-89 labeling for chimeric antigen receptor T cell PET imaging by comparing desferrioxamine and oxine. | Sci Rep | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A Moderate-Affinity Antibody-Drug Conjugate Targeting B7-H3 Exerts Potent Antitumor Efficacy. | Pharmaceuticals (Basel) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The Growth Supporting Role of ZDHHC11 Is Linked to the MEF2B-BCL6 Regulatory Circuit in Burkitt Lymphoma. | Int J Cancer | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Expression of Glycoprotein B (gB) Correlates With Poor Prognosis in Nasopharyngeal Carcinoma. | Cancer Sci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Dual-antigen recognition iPSC-derived CAR-T cells for B-cell malignancies: establishment of a COVID-19 vaccine synergy strategy. | Front Cell Dev Biol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Epigenetic activation of EBV BGLF4 determines antiviral-based regimen response in EBV+CNS lymphoproliferative disease. | Blood Neoplasia | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Nanobody-Engineered CLL-1 CAR T Cells: Optimizing Tumor-Specific Cytotoxicity and Minimizing Off-Tumor Toxicity. | Cancer Res Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Transgenic mouse-derived human monoclonal antibodies targeting EBV gp350 and gp42 provide basis for therapeutic development. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T-cell Antitumor Immunity through Metabolic Reprogramming. | Cancer Immunol Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| DNA-PKcs controls the cytotoxic T cell response to cancer and transplant allograft through regulating LAT-dependent signaling. | Cell Rep | 2026 | Its Methods give the RRID and name the line | PubMed | |
| CD8+ T-cell Antitumor Immunity via Human iNKT-DC Conjugates. | Cancer Immunol Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The Potential of the Gut Microbiota and Butyrate to Enhance CAR T-cell Therapy in Non-Hodgkin Lymphoma. | Clin Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Intein-based modular chimeric antigen receptor platform for specific CD19/CD20 co-targeting. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0511/papers